Novartis Competitors and Similar CompaniesClear all
Novartis's competitors and similar companies include Merck Group, Bausch + Lomb, Immunomedics, Gilead Sciences, Sanofi, AstraZeneca, Johnson & Johnson, Bayer and Pfizer.
 Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Bausch + Lomb Bausch + Lomb is a company that develops, manufactures, and markets eye health products. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Johnson & Johnson Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. | |||
Founding Date | Founding Date 1996 | Founding Date 1668 | Founding Date 1853 | Founding Date 1982 | Founding Date 1987 | Founding Date 1994 | Founding Date 1999 | Founding Date 1886 | Founding Date 1863 | Founding Date 1849 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||
Locations | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations Darmstadt, DE HQ Buenos Aires, AR Bayswater, AU Macquarie Park, AU Wien, AT Hoeilaart, BE Rio De Janeiro, BR see more | Locations Vaughan, CA HQ Buenos Aires, AR Vienna, AT Minsk, BY Aalst, BE Porto Alegre, BR São Paulo, BR see more | Locations Morris Plains, US HQ | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | Locations New Brunswick, US HQ Buenos Aires, AR Sydney, AU Vienna, AT Minsk, BY Beerse, BE Sofia, BG see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | |
Employees | Employees 75,883 | Employees 62,34615% decrease | Employees 13,500 | Employees 8914% decrease | Employees 18,0006% increase | Employees 82,878 | Employees 94,300 | Employees 138,1005% increase | Employees 88,5021% decrease | Employees 81,0008% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 71.6 b | Valuation ($) 7.3 b | Valuation ($) N/A | Valuation ($) 110.5 b | Valuation ($) 141.1 b | Valuation ($) 2.7 b | Valuation ($) 396.3 b | Valuation ($) 27.1 b | Valuation ($) 163.9 b |
Financial | ||||||||||
Revenue (est.) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) €21.1b (FY, 2025) | Revenue (est.) $5.1b (FY, 2025) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) $29.4b (FY, 2025) | Revenue (est.) €45.4b (FY, 2025) | Revenue (est.) $58.7b (FY, 2025) | Revenue (est.) $94.2b (FY, 2025) | Revenue (est.) €45.6b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) |
Cost of goods | Cost of goods $8.4b (FY, 2025) | Cost of goods €6.5b (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods $6.2b (FY, 2025) | Cost of goods €11.6b (FY, 2025) | Cost of goods $4.9b (FY, 2025) | Cost of goods $30.3b (FY, 2025) | Cost of goods €14b (FY, 2025) | Cost of goods $16.1b (FY, 2025) |
Gross profit | Gross profit $49.8b (FY, 2025) | Gross profit €15b (FY, 2025) | Gross profit N/A | Gross profit $295k (FY, 2019) | Gross profit $23.2b (FY, 2025) | Gross profit €37.6b (FY, 2025) | Gross profit $54.2b (FY, 2025) | Gross profit $63.9b (FY, 2025) | Gross profit €32.5b (FY, 2025) | Gross profit $46.5b (FY, 2025) |
Net income | Net income $14b (FY, 2025) | Net income €2.6b (FY, 2025) | Net income ($352m) (FY, 2025) | Net income ($357.3m) (FY, 2019) | Net income $8.5b (FY, 2025) | Net income €8b (FY, 2025) | Net income $10.2b (FY, 2025) | Net income $26.8b (FY, 2025) | Net income (€3.6b) (FY, 2025) | Net income $7.8b (FY, 2025) |
Operating ⚠ | ||||||||||
Countries | Countries N/A | Countries 66 (FY, 2021) | Countries N/A | Countries N/A | Countries 35 (FY, 2021) | Countries N/A | Countries 130 (FY, 2021) | Countries N/A | Countries 83 (FY, 2021) | Countries 200 (FY, 2024) |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 7 (FY, 2019) | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 1 (FY, 2021) | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 32 (FY, 2024) |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Products | Products N/A | Products 300 k (FY, 2021) | Products 400 (FY, 2022) | Products N/A | Products 21 (FY, 2021) | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 91 (FY, 2019) | Projects in R&D Pipeline 177 (FY, 2021) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A |
R&D Projects | R&D Projects N/A | R&D Projects N/A | R&D Projects 60 (FY, 2022) | R&D Projects N/A | R&D Projects N/A | R&D Projects N/A | R&D Projects N/A | R&D Projects N/A | R&D Projects N/A | R&D Projects 115 (FY, 2024) |
Registration Phase Products | Registration Phase Products 8 (FY, 2022) | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 5 (FY, 2024) |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 68 k (FY, 2019) | Suppliers N/A | Suppliers N/A | Suppliers 93.8 k (FY, 2021) | Suppliers N/A |
Funding | ||||||||||
Total funding raised | Total funding raised $ 6.5m | Total funding raised $ 121m | Total funding raised N/A | Total funding raised $ 30m | Total funding raised N/A | Total funding raised $ 310m | Total funding raised $ 1b | Total funding raised N/A | Total funding raised $ 3.5b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Merck Group
HQ
Darmstadt, DE
Employees
62,346↓ 15% decrease
Merck Group is a company that offers science and technology services.
View companyBausch + Lomb
HQ
Vaughan, CA
Employees
13,500
Bausch + Lomb is a company that develops, manufactures, and markets eye health products.
View companyImmunomedics
HQ
Morris Plains, US
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyGilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
View company